Clinical trials: Insulin Dependent Diabetes
- Condition Insulin Dependent Diabetes
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Diabetes Mellitus, Type 1
Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes
This feasibility study is a prospective, single center, multi-arm study evaluating possible enhancements to the SteadiSet extended wear infusion set.
- Trial name
- NCT07325461
- Testing
- SteadiSet Infusion Set
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes, Type I
Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
- Trial name
- NCT00308308
- Testing
- Technosphere Insulin, Active comparator
- Where
- 129 sites in United States, Argentina and 8 more
- Volunteers
- 589 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Prediabetes, Diabetes Type 1
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
G (guanine nucleotide binding) proteins associating with G protein-coupled receptors (GPCR) are key players in the pathogenesis of obesity and diabetes and are targets of pharmacotherapeutic inter-ventions.
- Conditions
- Prediabetes, Diabetes Type 1, Diabetes Type 2
- Trial name
- NCT02057497
- Volunteers
- healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 1 Diabetes
Stem Cell Educator Therapy in Type 1 Diabetes
The translational potential to the clinical applications of cord blood stem cells has increased enormously in recent years, mainly because of its unique advantages including no risk to the donor, no ethical issues, low risk of…
- Trial name
- NCT01350219
- Testing
- Stem Cell Educator
- Where
- 4 sites in China, Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Throne Biotechnologies Inc.
Hypoglycemia, Diabetes Mellitus, Type 1
A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion
A single center pilot study assessing the Vigilant Diabetes Management Companion for the prevention of recurrent nocturnal hypoglycemia in type I diabetes patients.
- Trial name
- NCT02906891
- Testing
- Vigilant Diabetes Management Application
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- InSpark Technologies, Inc.
Diabetes Mellitus, Non-Insulin-Dependent, Dyslipidemia
Safety Study of BMS-816336 in Healthy Male Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics following single oral doses of BMS-816336 in healthy male subjects.
- Trial name
- NCT00979368
- Testing
- BMS-816336
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 1
PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males
Primary objective: To demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of Gan \& Lee Insulin Aspart Injection with both EU-approved NovoRapid® and US-licensed NovoLog® (Reference Products) in healthy male…
- Trial name
- NCT04237129
- Testing
- Gan & Lee Insulin Aspart
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Healthy Volunteers and Diabetes Participants
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
- Trial name
- NCT07901595
- Testing
- PAL-119
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Paulex Bio Inc.
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and…
- Trial name
- NCT02113163
- Testing
- Metformin Eicosapentaenoate, Metformin HCl and Vascepa
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Thetis Pharmaceuticals LLC
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes, Diabetes Mellitus, Type 1
An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes
This study is conducted in the United States of America (USA). The aim of the study is to assess longitudinal variation of immune biomarkers in subjects at risk for development of type 1 diabetes (T1D).
- Trial name
- NCT01846312
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Health Adult Subjects, Obesity & Overweight
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
- Trial name
- NCT07675590
- Testing
- TIX100
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- TIXiMED, Inc.
Insulin Resistance, Lipohypertrophy
De-tensioning Patch, in Subjects With Type 1 Diabetes and Lipohypertrophy
This is a single-center, single-cohort, open, repeated-application study. Baseline assessments will include a Hyperinsulinemic clamp after injection of 0.15 U/kg body weight of insulin lispro in the target LH lesion, as well as a…
- Trial name
- NCT06025513
- Testing
- Embrace Patch
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Neodyne Biosciences, Inc.
Healthy, Diabetes
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The purpose is to evaluate safety and tolerability of a range of single doses of subcutaneous insulin 338.
- Conditions
- Healthy, Diabetes, Diabetes Mellitus, Type 1
- Trial name
- NCT02220296
- Testing
- Insulin 338, insulin glargine
- Where
- Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes
This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD)…
- Trial name
- NCT07889505
- Testing
- PS1
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Type 1 Diabetes
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
- Trial name
- NCT05794581
- Testing
- CT-868, Victoza
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Type 1 Diabetes
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
In this study, subjects with insufficient metabolic control despite optimized basal-bolus injection regimens were randomily assigned to either the Mini- Med Paradigm REAL-Time insulin pump (PRT), an insulin pump that can receive…
- Trial name
- RTD (NCT00441129)
- Testing
- Minimed paradigm Real Time Sytem, Minimed Paradigm 512/712 Insulin pump
- Where
- 8 sites in France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity
Investigator initiated, randomised, placebo-controlled, double-blind, multi-centre primary intervention study to assess whether daily administration of B.
- Trial name
- SINT1A (NCT04769037)
- Testing
- B. infantis
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 1,149 people, healthy volunteers welcome
- Sponsor
- Helmholtz Zentrum München
Hypertension
Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes
A study comparing the antihypertensives Valsartan and Lisinporil when doses are in the morning and comparing a morning dose of Valsartan with an evening dose.
- Trial name
- NCT00241124
- Testing
- valsartan, lisinopril
- Where
- Germany
- Volunteers
- 1,099 people, healthy volunteers welcome
- Sponsor
- Novartis